OncoMatch/Clinical Trials/NCT07314073

[18F]FES PET/CT for the Detection of Distant Metastasis in Low-grade ER-positive Stage III Breast Cancer

Is NCT07314073 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for stage iii breast cancer.

Phase 2RecruitingAsan Medical CenterNCT07314073Data as of May 2026

This study aims to evaluate the detection rate of distant metastases using \[18F\]FES PET/CT in patients with low-grade, ER-positive stage III breast cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Breast Carcinoma

Biomarker criteria

Required: ESR1 positive (positive)

Disease stage

Required: Stage IIIA, IIIB, IIIC

Grade: 12 (histologic)

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: systemic therapy

Subjects who are currently receiving systemic therapy for breast cancer (e.g., neoadjuvant chemotherapy, hormonal therapy)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify